TRISCEND JAPAN Study
← catalyst calendarSponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
45estimated
Sites
8
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-06 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Tricuspid Valve Regurgitation
- Heart Valve Diseases
- Cardiovascular Diseases
Intervention
- Device: Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System
Primary outcomes
what the primary-completion date above is the date OFAll-Cause Mortality
measured 1 year
Heart Failure Hospitalization
measured 1 year
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed